Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer.
Silvio Ken GarattiniMarta BonottoLuca PorcuElena OngaroLorenzo GerratanaDebora BasileAnnamaria ParnofielloGiacomo PelizzariFrancesco CortiulaCarla CorvajaMariaelena CasagrandeGiovanni Gerardo CardellinoAngela BuonadonnaGiuseppe AprileFabio PuglisiGianpiero FasolaNicoletta PellaPublished in: Future oncology (London, England) (2020)
Background: 'Drug holidays' (DH) for metastatic colorectal cancer (mCRC) were introduced to preserve quality of life. We studied factors associated to a DH offer in first line. Materials & methods: We retrospectively analyzed 754 consecutive patients treated with chemotherapy for mCRC in two Italian institutions between 2005 and 2017. Associations between baseline clinical-pathological factors and DH (56 or more days of treatment interruption) were investigated. Results: In 754 patients, previous metastasectomy, previous thermoablation and previous surgery of primary tumor were independently associated with DH. Excluding procedures or clinical trials: primary rectal cancer and resection of primary tumor were significantly associated to DH. Conclusions: DH was offered to patients with lower burden of disease, but further investigations are needed to safely guide a holiday strategy.
Keyphrases
- metastatic colorectal cancer
- clinical trial
- rectal cancer
- end stage renal disease
- locally advanced
- ejection fraction
- newly diagnosed
- minimally invasive
- squamous cell carcinoma
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- coronary artery bypass
- patient reported outcomes
- adverse drug
- drug induced
- study protocol
- atomic force microscopy
- high speed